Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Shanghai Kangli, has received approval from the National Medical Products Administration for the production of Tamsulosin Hydrochloride raw material, indicating a significant step in the company's product portfolio expansion [1] Group 1: Company Developments - Shanghai Kangli submitted a registration application for Tamsulosin Hydrochloride in July 2024, which has been accepted [1] - The company has invested approximately 1.5 million yuan in research and development for this product [1] Group 2: Market Context - The procurement amount for Tamsulosin Hydrochloride formulations in hospitals across mainland China is reported to be 413.8275 million yuan for 2024 [1] - The approval allows for domestic sales of the raw material, which may provide valuable experience for future applications, although it is not expected to significantly impact current performance [1]

Core Viewpoint - The company, Shengnuo Biopharmaceutical (688117.SH), announced its participation in the national centralized procurement process for pharmaceuticals, marking the first nationwide unified continuation procurement for chemical drugs [1] Group 1: Procurement Participation - The company's wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., is involved in the first to eighth batches of the national centralized procurement [1] - This continuation procurement is significant as it represents the first nationwide unified continuation for chemical drugs organized by the state [1] Group 2: Selected Products - The company’s products, including Acetate Octreotide Injection (selected in the seventh batch), Acetate Atosiban Injection (selected in the eighth batch), and Somatostatin Injection (selected in the eighth batch), are among those proposed for selection in this new round of procurement [1] - Additionally, the company has new products proposed for selection, including Thymosin Alpha 1 Injection and Exenatide Injection [1]

Core Viewpoint - The company, Borui Pharmaceutical (688166.SH), announced that its wholly-owned subsidiary, Borui Pharmaceutical (Suzhou) Co., Ltd., participated in the continuation procurement of drugs whose agreements have expired, with four products, including Agachuban injection, proposed for selection in the upcoming procurement [1] Group 1 - The proposed selected products for continuation procurement include four drugs, with a total sales revenue of 88.8475 million yuan in the first three quarters of 2025, accounting for 10.16% of the company's total revenue during the same period [1] - Medical institutions will prioritize the use of the selected drugs during the procurement cycle, ensuring the completion of the agreed purchase volume [1] - If contracts are signed and implemented, it will further expand the sales volume, increase market share, and enhance the company's brand image [1]

Group 1 - The company, Xuantai Pharmaceutical (688247.SH), currently has no involvement in the development of AI innovative drugs [1]

格隆汇2月11日丨博瑞医药（维权）(688166.SH)公布，公司全资子公司博瑞制药（苏州）有限公司 （称"博瑞制药"）参加了国家组织集采药品协议期满品种接续采购办公室(称"接续采购办公室")组织的 集采药品协议期满品种接续采购(称"本次接续采购")。根据接续采购办公室于2026年2月10日发布的 《国家组织集采药品协议期满品种接续采购拟中选结果公示》，公司部分药品拟中选本次接续采购。 本次接续采购品种为第1-8批国家组织集采协议期满的品种，约定采购量以医药机构填报各企业采购品 种需求量为基数，按照中选价格梯度确定带量比例。采购周期自中选结果实际执行日起至2028年12月31 日。 公司上述拟中选的4个产品2025年前三季度合计销售额为8,884.75万元，占公司2025年前三季度营业收入 比例为10.16%。在采购周期内，医疗机构将优先使用本次药品接续采购中选药品，并确保完成约定采 购量。若后续签订采购合同并实施，将进一步扩大产品的销量，提高市场占有率，提升公司品牌形象。 ...

Core Viewpoint - Hansen Pharmaceutical (002412) has responded to investor inquiries regarding its products aimed at improving gastrointestinal function, highlighting a range of offerings in this category [1] Product Offerings - The company, including its wholly-owned subsidiary Yunnan Yongzitang Pharmaceutical Co., Ltd., has several products targeting gastrointestinal health, including: - Si Mo Tang Oral Liquid - Chen Xiang Lu Bai Lu Pian - Ba Wei Rou Gui Jiao Nang - Wei Chang Ling Jiao Nang - Tong Shu Kou Shuang Jiao Nang - Ku Shen Jiao Nang [1]

Core Viewpoint - The company, Huaren Pharmaceutical, is expected to report a significant loss in 2025 due to substantial goodwill impairment related to two subsidiaries, while also expanding its renal business capacity and experiencing executive changes [1][2]. Financial Performance - The company forecasts a net profit attributable to shareholders of between -480 million yuan and -360 million yuan for 2025, primarily due to goodwill impairment of 440 million to 540 million yuan related to subsidiaries Anhui Hengxing Pharmaceutical and Guangxi Yuyuan Pharmaceutical [2] - Excluding the impairment impact, the core business net profit is projected to be between 60 million and 80 million yuan, indicating stabilization in core operations [2]. Company Status - The goodwill impairment stems from unmet performance commitments following the acquisition of Anhui Hengxing Pharmaceutical in 2021, with ongoing litigation regarding a 256 million yuan payment to the original equity transferor, creating uncertainty [3]. - The company plans to enhance capacity, expand channels, and optimize product structure for the involved subsidiaries to gradually improve profitability [3]. Capacity Expansion - In November 2025, the company launched the first production line for peritoneal dialysis solution at its Rizhao factory, increasing annual capacity to 51 million bags, with a second line under testing that will raise total capacity to 62 million bags, reinforcing market supply capabilities [4]. - The renal business remains a strategic focus, with sales and revenue from peritoneal dialysis solutions continuing to grow in 2025 [4]. Executive Changes - In December 2025, a major shareholder, Huaren Century Group, reduced its stake from 7.06% to 6.83%, which the company stated did not affect control or operations [5]. - The company experienced an unexpected change in leadership when Chairman Zhang Li resigned for personal reasons on August 26, with Director Hou Ruipeng assuming responsibilities, described as a personal matter by the company [5]. Strategic Advancement - The company is advancing its "raw materials + formulations + packaging" integrated strategy, enhancing production efficiency through digital upgrades and expanding into high-value product matrices in respiratory and narcotic fields to address pricing pressures from centralized procurement policies [6]. - In 2025, the company obtained multiple product approvals and patents to strengthen its long-term competitiveness [6].

Core Viewpoint - The company, Shengnuo Biopharmaceutical (688117.SH), has participated in the national centralized procurement process for the first to eighth batches of drugs, marking a significant step in expanding its market presence and enhancing competitiveness in the peptide pharmaceutical market [1] Group 1: Procurement Participation - The company’s wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., has engaged in the new round of centralized procurement organized by the state, which is the first nationwide unified continuation of centralized procurement for chemical drugs [1] - The company’s products, including Acetate Octreotide Injection (selected in the seventh batch), Acetate Atosiban Injection (selected in the eighth batch), and Somatostatin Injection (selected in the eighth batch), are among those proposed for selection in this new round of procurement [1] Group 2: Market Impact - The centralized procurement will prioritize the use of selected drugs by medical institutions, ensuring the completion of the agreed procurement volume [1] - The selection in this procurement round reflects the stability and reliability of the company’s drug quality, which is expected to further expand the sales scale of the selected products and increase market share [1] - The implementation of the procurement contract is anticipated to positively impact the company's operational development and strengthen its competitiveness in the peptide pharmaceutical market [1]

Core Viewpoint - The company Fu Yuan Pharmaceutical (601089.SH) announced participation in the national organized procurement for drugs whose agreements are expiring, with selected products including Ezetimibe tablets, which are expected to positively impact future operating performance despite a decrease in sales prices [1] Group 1: Procurement Participation - The company participated in the national organized procurement for drugs with expiring agreements on February 9, 2026 [1] - The results of the procurement are expected to be implemented by the end of March 2026, with provincial medical institutions signing procurement contracts based on the selected results [1] Group 2: Market Impact - Selected products in this procurement, including Ezetimibe tablets, are anticipated to have a decrease in sales prices [1] - The company aims to stabilize its existing market share and potentially increase market penetration due to brand influence and reliable supply capabilities [1] - The positive impact on the company's future operating performance is expected as a result of these developments [1]

Core Viewpoint - The company, Fuyuan Pharmaceutical (601089.SH), participated in the national organized procurement for drugs whose agreements are expiring, with selected products expected to positively impact future business performance despite a decrease in sales prices [1] Group 1: Procurement Participation - The company announced its participation in the national organized procurement for drugs with expiring agreements on February 9, 2026 [1] - The results of the procurement are expected to be implemented by the end of March 2026, with provincial medical institutions signing contracts based on the selected results [1] Group 2: Selected Products and Market Impact - The company has several products, including Ezetimibe tablets, proposed for selection in this procurement [1] - Although the sales prices of selected drugs are expected to decrease, the company aims to stabilize its existing market share and potentially increase market penetration due to its brand influence and reliable supply capabilities [1]